论文部分内容阅读
本文通过对鼠胶质瘤G—422传代模型从半数抑制量0.5mg/kg BCNU(卡氮芥,Carmustine)开始诱导,经过七代传代,BCNU量增加100倍以上后,诱导组与对照组小鼠皮下瘤结节大小和荷瘤鼠寿命无显著差异,并且诱导组能稳定传代,保持对BCNU的耐受性,从而建成耐药细胞系。用非毒剂量利血平治疗后,耐药组肿瘤显著缩小,为进一步研究胶质瘤细胞耐药特性和治疗对策奠定了基础。
In this study, the G-422 mouse model of glioma was induced with a half-inhibition dose of 0.5 mg/kg BCNU (Carmustine). After seven generations of passage, the BCNU amount increased by more than 100-fold, and the induction group was smaller than the control group. There was no significant difference in the tumor subcutaneous tumor nodule size and life span of tumor-bearing mice, and the induction group could stably pass and maintain the tolerance to BCNU, thus establishing a drug-resistant cell line. After treatment with non-toxic dose of reserpine, the tumors in the drug-resistant group were significantly reduced, which laid the foundation for further study of drug resistance characteristics and therapeutic strategies of glioma cells.